Gepotidacin inhibits DNA replication via two ... could claim 10 million deaths a year by 2050. "The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in ...

Gepotidacin is an oral ... and vulvovaginal candidiasis. “The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in women,” said Tony Wood, Chief Scientific ...

GSK Gepotidacin (Blujepa) nabs FDA approval as the first in a new class of oral antibiotics for uncomplicated UTIs in nearly 30 years Structurally Gepotidacin, a triazaacenaphthylene bearing ...

The US Food and Drug Administration (FDA) recently approved Blujepa (gepotidacin), a ground-breaking oral antibiotic for treating uncomplicated urinary tract infections (UTIs). This is the first new ...

You can follow Urology Times’ coverage of the meeting here. REFERENCES 1. Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and ...

The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics for uncomplicated urinary tract infections (uUTIs) in over 20 years.

Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes. (HealthDay News) — For patients with symptomatic peripheral ...

Amvuttra (vutrisiran) Transthyretin-directed small interfering RNA therapeutic Treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce ...